Spyre Therapeutics Stock Slides 12% After $350M Offering Priced at $85
SYRE has more than doubled off its 52-week low of $15.86 on elevated volume (1.9× avg).
Summary
Spyre Therapeutics priced a $350 million public offering of 4,117,648 shares at $85 per share, a 4.5% discount to the last close. Underwriting discounts are $5.10 per share, with net proceeds of approximately $328.7 million. Underwriters have a 30-day option to purchase up to 617,647 additional shares. The stock fell 12% to $81.83 in midday trading Tuesday, reflecting dilution concerns. Proceeds will fund drug development across gastroenterology, rheumatology, and dermatology. The offering is expected to close Wednesday. This follows positive Phase 2 data for SPY003 in ulcerative colitis announced in September.
Updated with an SEC 424B5 filing · What changed
Updates
· SEC 424B5 — The 424B5 prospectus supplement details the offering: 4,117,648 shares at $85.00, underwriting discounts of $5.10 per share, net proceeds of approximately $328.7 million, and a 30-day underwriters' option for 617,647 additional shares.
At the time of this announcement, SYRE was trading at $81.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $15.86 to $110.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.